James W. Broderick is Director at OncoMed Pharmaceuticals Inc (OMED). They have made 1 open-market trade across 1 company since 2013, most recently 2013-07-23.
CIK 0001553356
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.2M since 2013, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OMED | 710,526 | $632K |
Shares reported on the most recent Form 4, priced at the 2013-07-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OMED | BUY | 2013-07-23 | 2013-07-23 | $17.00 | $1.2M | -32.1% | -0.5% | -0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.